Detailed Information on Publication Record
2005
Význam mitoticko-apoptotického indexu a DNA flow-cytometrie v prognóze karcinom hlavy a krku
SMILEK, Pavel, Ladislav DUEK, Karel VESELÝ, Rom KOSTICA, Jan ROTTENBERG et. al.Basic information
Original name
Význam mitoticko-apoptotického indexu a DNA flow-cytometrie v prognóze karcinom hlavy a krku
Name in Czech
Význam mitoticko-apoptotického indexu a DNA flow-cytometrie v prognóze karcinom hlavy a krku
Name (in English)
The Importance of MitoticApoptotic Index and DNA Flow Cytometry in the Prognosis of Head and Neck Cancer
Authors
SMILEK, Pavel (203 Czech Republic, guarantor), Ladislav DUEK (203 Czech Republic), Karel VESELÝ (203 Czech Republic), Rom KOSTICA (203 Czech Republic) and Jan ROTTENBERG (203 Czech Republic)
Edition
Otolaryngologie a foniatrie, Praha, eská lékaská spolenosti J.E. Purkyn, 2005, 1210-7867
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/05:00014296
Organization unit
Faculty of Medicine
Keywords in English
head and neck cancer; prognosis; proliferation-apoptotic index; DNA flow cytometry
Změněno: 19/12/2005 14:01, doc. MUDr. Pavel Smilek, Ph.D.
V originále
Souhrn: Cílem studie byla analýza prognostického významu p53, Ki-67, mitotického a apoptotického indexu a flow cytometrické analýzy karcinom hlavy a krku. Materiál a metody: Hodnocen soubor 77 nemocných s karcinomem hlavy a krku léených na Klinice otorinolaryngologie a chirurgie hlavy a krku v Brn v letech 20032005. Vedle obvyklých vyetení byla provedena flow cytometrická analýza DNA a imunohistochemicky stanoven marker Ki-67 a p53. Výsledky: Se III. a IV. klinickým stadiem TNM klasifikace bylo léeno 83,1 % nemocných. Histopatologický grading 12 mlo 77,9 % nemocných. Medián doby celkového peití byl 39,7 msíc. Vývoj rizika onemocnní bhem prvních 6 msíc byl nezávislý na stagingu a lokalizaci. Málo pokroilé nádory (T12) a mén diferencované nádory (G34) mly lepí prognózu (p=0,034). Závr: Hodnocení kinetických parametr bunného cyklu odhalilo významn nií podíl bunk v S fázi u nádor se patnou prognózou. Nádory s pímou progresí ihned po léb dále vykazují statisticky vyí podíl bunk v G2/M fázi
In English
The objective of the study was to analyze prognostic importance of the biomarkers p53, Ki67, mitotic and apoptotic index and flow cytometry analysis of the cell cycle of head and neck cancer in relation to Event Free Survival (EFS) and Overall Survival (OS). Material and Methods: the analysis was made in a group of 77 patients with head and neck cancer, who were treated at the Clinic of Otorhinolaryngology and Head and Neck Surgery at Brno in the years 20032005. In addition to common types of examinations (determination of localization, extent and possible metastases of the tumor histological examination), flow cytometric analysis of DNA was performed and the Ki-67 and p53 markers were examined by immunohistochemistry. Results: the tumor was localized in 31.2% of patients in nasopharynx and on the lateral wall of oropharynx, in 58.4% on the tongue root and in supraglottis and in 10.4% in hypopharynx. The IIIrd and IVth clinical stage of TNM classification was encoundeted in 83.1% of the treated patients. Histopathological grading 1 or 2 was established in 77.9% of patients. The median survival was 39.7 months. The evolution of the disease risk during the first 6 months appears to be independent of common clinical categories, specifically on staging and localization. The prognosis of low-advanced tumors (T12) and simultaneous low-differentiated tumors (G34) proved to be better (p=0.034). The prognosis of diploid and p53 negative tumors was better (p=0.222). Conclusions: the evaluation of kinetic parameters of the cell cycle univocally revealed a significantly lower proportion of cells in the S phase (named SPF) in tumor of poor prognosis. Tumors with a direct progression immediately after the therapy included a significantly higher proportion the cells in G2/M phase. The definition of poor or good prognosis is based on the ratio of SPF and G1/M phase.
Links
| MSM 141100003, plan (intention) |
|